<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>ar356</ui>
   <ji>ARJ</ji>
   <fm>
      <dochead>Meeting abstract</dochead>
      <bibl>
         <title>
            <p>Clinical evaluation of autologous chondrocytes for joint repair</p>
         </title>
         <aug>
            <au id="A1">
               <snm>Brittberg</snm>
               <fnm>M</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A2">
               <snm>Sj&#246;gren-Jansson</snm>
               <fnm>E</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A3">
               <snm>Peterson</snm>
               <fnm>L</fnm>
               <insr iid="I3"/>
            </au>
            <au id="A4">
               <snm>Lindahl</snm>
               <fnm>A</fnm>
               <insr iid="I2"/>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>Cartilage research Unit, G&#246;teborg University, Department of Orthopaedics, Kungsbacka Hospital, Sweden</p>
            </ins>
            <ins id="I2">
               <p>Institute of Laboratory Medicine, Sahlgrenska University Hospital, Sweden</p>
            </ins>
            <ins id="I3">
               <p>Gothenburg Medical Center, G&#246;teborg, Sweden</p>
            </ins>
         </insg>
         <source>Arthritis Res</source>
         <supplement>
            <title>
               <p>Innovative Rheumatology: Gene and Cell Therapies of Arthritis and Related Autoimmune Disorders. Second International Meeting</p>
            </title>
            <note>Meeting abstracts</note>
         </supplement>
         <conference>
            <title>
               <p>Innovative Rheumatology: Gene and Cell Therapies of Arthritis and Related Autoimmune Disorders. Second International Meeting</p>
            </title>
            <location>Montpellier, France</location>
            <date-range>17&#8211;18 May 2001</date-range>
         </conference>
         <issn>1465-9905</issn>
         <pubdate>2001</pubdate>
         <volume>3</volume>
         <issue>Suppl 1</issue>
         <fpage>P3</fpage>
         <xrefbib>
            <pubid idtype="doi">10.1186/ar356</pubid>
         </xrefbib>
      </bibl>
      <history>
         <rec>
            <date>
               <day>6</day>
               <month>4</month>
               <year>2001</year>
            </date>
         </rec>
         <pub>
            <date>
               <day>25</day>
               <month>4</month>
               <year>2001</year>
            </date>
         </pub>
      </history>
      <cpyrt>
         <year>2001</year>
         <collab>BioMed Central Ltd</collab>
      </cpyrt>
   </fm>
   <meta>
      <classifications>
         <classification type="BMC" subtype="old_arx_id">ar-3-s1-p3</classification>
      </classifications>
   </meta>
   <bdy>
      <sec>
         <st>
            <p/>
         </st>
         <p>Autologous cultured chondrocyte transplantation was introduced in Sweden in 1987 for the treatment of full thickness chondral defects of the knee. The results from the first 219 patients with a follow up of 2&#8211;10 years treated using this technique are reported. Patients were assessed with three types of endpoints: patient and physician derived clinical rating scales, arthroscopy assessments of cartilage fill, integration, and surface hardness and histology of graft biopsies. There was a high percentage of good to excellent results (84&#8211;90%) in patients with different types of single femoral condyle lesions, while other types of lesions had a lower degree of success (mean 74%). Furthermore, the long-term durability of the grafted area has been evaluated in a group of 61 patients with femoral condyle and patellar lesions who where followed for a mean of 7.4 (range 5&#8211;11) years and where the durability was calculated as the comparison between the long-term follow up and clinical status at 2 years post surgery. At 2 years, 50 of 61 patients treated were classified as satisfactory and at mean 7.4 years follow up, 51 of 61 were graded satisfactory. Twelve defects tested biomechanically demonstrated stiffness values &#8805; 90% of normal in 67% of the patients and 8/12 graft biopsies showed hyaline-like characteristics. The good clinical long-term outcomes of autologous chondrocyte transplantation in these studies are encouraging. Future research programs contain a series of randomized studies on the different clinical repair methods available and more research on the cell sources, matrices and repair tissue evaluation.</p>
      </sec>
   </bdy>
</art>
